87 results about "P-selectin" patented technology

Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.

The invention relates to isolated hemangioblast cells. Hematopoietic and endothelial cells are postulated to be derived from a common progenitor, hemangioblast. While hemangioblast has been isolated retrospectively during embryonic stem cell differentiation, it has not been isolated from embryos or from bone marrow. Prospectively stable clonal cell lines have been isolated from mammalian embryos, from embryonic stem cells and from mammalian bone marrow that can differentiate in vitro into tubular structures with both endothelial and hematopoietic markers such as CD34, CD31, Flk-1, TIE2, P-selectin, Sca-1, thy-1, CD45, and smooth muscle actin. Gene expression profiles in the undifferentiated and differentiated cells were consistent with endothelial and hematopoietic differentiation potential. Transplantation studies in isogenic or immunodeficient mice demonstrated that these cells were not tumorigenic. In an appropriate microenvironment, the cells incorporate into the vasculature and participate in hematopoiesis.

Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids).

The invention discloses a novel heptacyclic compound (2'S,5'S)-tetrahydropyrazine [1',2':1,6] and bis{2,3,4,9-tetrahydro-1H-pyridine [3,4-b] indole}-1',4'-diketone (THPDTPI for short), a preparation method thereof, and antithrombosis action, anti-inflammatory action, anti-tumor action, free radical scavenging action and P-selectin expression inhibition action thereof. Therefore, the invention discloses application of the THPDTPI in preparing a medicament which takes the P-selectin as a target and simultaneously inhibits thrombosis, inflammation and tumor. Because thrombosis and inflammation are the most popular complications in patients with tumor, the THPDTPI not only can treat tumor, but also can prevent patients with tumor from complicating thrombosis and inflammation. The THPDTPI disclosed by the invention has favorable clinical application prospects.

The invention discloses a novel heptacyclic compound (2'S,5'S)-tetrahydropyrazine[1',2':1,6]bis{(1S)-1-methyl-2,3,4,9-tetrahydro-1H-pyridine[3,4-b]diindole}-1',4'-diketone (ZMC for short), discloses apreparation method thereof, discloses an anti- thrombosis function thereof, discloses an anti-inflammation effect thereof, disclosed an anti-tumor effect thereof, and further discloses a free radicalscavenging effect and a P-selectin expression inhibiting effect thereof. Thus, the invention discloses application of the ZMC to preparation of a P-selectin-targeted medicament capable of inhibitingthrombosis, inflammation and tumors. Since the thrombosis and the inflammation are most common complications of tumor patients, the ZMC disclosed by the invention can be used for not only treating thetumors, but also preventing the complications of the thrombosis and the inflammation in the tumor patients. The ZMC disclosed by the invention has a good clinical application prospect.

Compositions and methods for detecting various disorders with targeted microbubbles are disclosed. Specifically, microbubbles comprising glycoprotein Ib (GPIb), ligands for VCAM-1, and ligands for P-selectin such as PSGL-1 are disclosed. Also disclosed are methods for using targeted microbubbles to detect cardiovascular disease comprising administering the disclosed microbubbles to a subject and detecting the microbubbles in the vasculature using ultrasound.

Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Arg-Gly-Asp-Val, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb/IIIa expression, and discloses the activity of inhibiting the P-selectin expressionin vivo. Therefore, the invention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb/IIIa antagonist and the application in preparing P-selectin antagonist. The formulas are shown in the decription.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Tyr-Ile-Gly-Ser-Lys, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb/IIIa expression, and discloses the activity of inhibiting the P-selectin expression in vivo. Therefore,the invention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb/IIIa antagonist and the application in preparing P-selectin antagonist. The formulas are shown in the decription.

A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.

The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.

The invention discloses application of an aptamer in recognition of L selectin and combination with L selectin. The condition that the aptamer Sgc-3b can specifically recognize L selectin and can be specifically combined with L selectin is discovered for the first time, and an L selectin detecting method is established by utilizing the combination of specificities of the aptamer Sgc-3b and L selectin. Experiments prove that the aptamer Sgc-3b has the characteristics of being high in affinity, strong in specificity, free of immunogenicity and toxicity, and the like, and the L selectin detecting method established based on the aptamer Sgc-3b can be used for detection of L selectin expression and diagnosis of related diseases.

Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.

The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.

The present invention relates to compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such compounds comprising a peptide with an amino acid sequence XA_xA₃A₁A₂A₁Y, or a functional equivalent of said peptide. In addition, the invention relates to methods for preparing such compounds, to the use of such compounds in therapeutic or diagnostic methods and in pharmaceutical compositions, to nucleic acids encoding for proteinaceous materials comprising the amino acid sequences of said compounds, to gene delivery vehicles comprising such nucleic acids, to binding molecules binding to said compounds, and to a method for determining whether a compound is capable of binding to P-selectin.

This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of using these fusion proteins as thrombolytic agents, and processes for synthesizing these fusion proteins are also described herein.

The invention discloses a zebra fish P-selectin gene and a protein. The nucleotide sequence of the zebra fish P-selectin gene is shown as SEQ ID NO.1, and the encoded protein sequence is shown as SEQ ID NO.2. The zebra fish P-selectin gene can be used for constructing transgenic zebra fishes. The constructed transgenic zebra fishes can be used for researching the generation mechanism of thrombotic diseases and sieving the antithrombotics. The zebra fish P-selectin gene and the encoded gene can be used for preparing drugs for preventing and treating the thrombotic diseases.

The invention provides 3 novel antithrombotic quasi-peptides disclosed as general formula I, a molecular simulation method of the 3 novel antithrombotic quasi-peptides, a preparation method of the 3 novel antithrombotic quasi-peptides, inhibiting action of the 3 novel antithrombotic quasi-peptides on expression of glycoprotein IIb/IIIa and P-lectin, anti-thrombocyte aggregation action of the 3 novel antithrombotic quasi-peptides, and antithrombotic action of the 3 novel antithrombotic quasi-peptides on a rat thrombosis model. Therefore, the invention provides clinical application prospects of the 3 novel antithrombotic quasi-peptides disclosed as general formula I as an antithrombotic agent. In the general formula I, AA represents Ser or Val or Phe residue.

P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.

Compositions and kits useful for the treatment of myocardial infarction comprise (i) P-selectin-targeted carriers (e.g., P-selectin-targeted liposomes, quantum dots or biodegradable nanoparticles) comprising VEGF and (ii) MSCs.

P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.